Biologics Market Size, Growth, Demands Outlook and Forecasts to 2030

According to the research report, the global biologics market size is expected to touch USD 719.84 Billion by 2030, from USD 393.53 Billion in 2022, growing with a significant CAGR of 7.8% from 2022 to 2030. 

The biologics report offers a comprehensive study of the current state expected at the major drivers, market strategies, and key vendors’ growth. The report presents energetic visions to conclude and study the market size, market hopes, and competitive surroundings. The research also focuses on the important achievements of the market, research & development, and regional growth of the leading competitors operating in the market. The current trends of the global biologics in conjunction with the geographical landscape of this vertical have also been included in this report.

The report offers intricate dynamics about different aspects of the global biologics market, which aids companies operating in the market in making strategic development decisions. The study also elaborates on significant changes that are highly anticipated to configure growth of the global biologics during the forecast period. It also includes a key indicator assessment that highlights growth prospects of this market and estimates statistics related to growth of the market in terms of value (US$ Mn) and volume (tons).

Sample Link @ https://www.precedenceresearch.com/sample/1638

 Report Scope of the Biologics Market

Report Coverage	Details
Market Size by 2030	USD 719.84 Billion
Growth Rate from 2022 to 2030	CAGR of 7.8%
Largest Market	North America
Fastest Growing Makret	Asia Pacific
Base Year	2021
Forecast Period	2022 to 2030
Segments Covered	Source, Product, Disease, Manufacturing, Route of Administration, Drug Classification, Mode of Purchase, Distribution Channel, Geography

This study covers a detailed segmentation of the global biologics market, along with key information and a competition outlook. The report mentions company profiles of players that are currently dominating the global biologics market, wherein various developments, expansions, and winning strategies practiced and implemented by leading players have been presented in detail.

Key Players

• Eli Lilly & Company
• Samsung Biologics
• F Hoffman La Roche
• Celltrion Addgene
• Amgen
• Abbvie Inc.
• Sanofi
• Pfizer Inc.
• Merck & Co. Inc
• Novo Nordisk A/S

Market Segmentation

 By Source

• Microbial
• Mammalian
• Others

By Product

• MABs
• Vaccines
• Hormones
• Therapeutic Enzymes
• Recombinant Proteins
• Antisense, RNAi & Molecular Therapy
• Blood Factors and Anticoagulants
• Allergenic extracts
• Human Cells and Tissues
• Proteins
• Gene Therapies
• Cellular Therapies
• Others

By Disease

• Oncology
• Immunological Disorders
• Cardiovascular Disorders
• Hematological Disorders
• Others

By Manufacturing

• Outsourced
• In-house

By Route of Administration

• Oral
• Others (IV and IP)

By Drug Classification

• Branded Drugs
• Generic Drugs

By Mode of Purchase

• Prescription Drugs
• Over-The-Counter (OTC) Drugs

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Geography

• North America
• U.S.
• Canada
• Europe
• U.K.
• Germany
• France
• Asia-Pacific
• China
• India
• Japan
• South Korea
• Malaysia
• Philippines
• Latin America
• Brazil
• Rest of Latin America
• Middle East & Africa (MEA)
• GCC
• North Africa
• South Africa
• Rest of the Middle East & Africa

Research Methodology

The research methodology adopted by analysts for compiling the global biologics report is based on detailed primary as well as secondary research. With the help of in-depth insights of the market-affiliated information that is obtained and legitimated by market-admissible resources, analysts have offered riveting observations and authentic forecasts for the global market.

During the primary research phase, analysts interviewed market stakeholders, investors, brand managers, vice presidents, and sales and marketing managers. Based on data obtained through interviews of genuine resources, analysts have emphasized the changing scenario of the global market.

For secondary research, analysts scrutinized numerous annual report publications, white papers, market association publications, and company websites to obtain the necessary understanding of the global biologics market.

TABLE OF CONTENT

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. Market Dynamics Analysis and Trends

5.1. Market Dynamics

5.1.1. Market Drivers

5.1.2. Market Restraints

5.1.3. Market Opportunities

5.2. Porter’s Five Forces Analysis

5.2.1. Bargaining power of suppliers

5.2.2. Bargaining power of buyers

5.2.3. Threat of substitute

5.2.4. Threat of new entrants

5.2.5. Degree of competition

Chapter 6. Competitive Landscape

6.1.1. Company Market Share/Positioning Analysis

6.1.2. Key Strategies Adopted by Players

6.1.3. Vendor Landscape

6.1.3.1. List of Suppliers

6.1.3.2. List of Buyers

Chapter 7. Global Biologics Market, By Source

7.1. Biologics Market, by Source, 2022-2030

7.1.1. Microbial

7.1.1.1. Market Revenue and Forecast (2017-2030)

7.1.2. Mammalian

7.1.2.1. Market Revenue and Forecast (2017-2030)

7.1.3. Other

7.1.3.1. Market Revenue and Forecast (2017-2030)

Chapter 8. Global Biologics Market, By Product

8.1. Biologics Market, by Product, 2022-2030

8.1.1. MABs

8.1.1.1. Market Revenue and Forecast (2017-2030)

8.1.2. Vaccines

8.1.2.1. Market Revenue and Forecast (2017-2030)

8.1.3. Hormones

8.1.3.1. Market Revenue and Forecast (2017-2030)

8.1.4. Therapeutic Enzymes

8.1.4.1. Market Revenue and Forecast (2017-2030)

8.1.5. Recombinant Proteins

8.1.5.1. Market Revenue and Forecast (2017-2030)

8.1.6. Antisense, RNAi & Molecular Therapy

8.1.6.1. Market Revenue and Forecast (2017-2030)

8.1.7. Blood Factors and Anticoagulants

8.1.7.1. Market Revenue and Forecast (2017-2030)

8.1.8. Allergenic extracts

8.1.8.1. Market Revenue and Forecast (2017-2030)

8.1.9. Cellular Therapies

8.1.9.1. Market Revenue and Forecast (2017-2030)

8.1.10. Gene Therapies

8.1.10.1. Market Revenue and Forecast (2017-2030)

8.1.11. Proteins

8.1.11.1. Market Revenue and Forecast (2017-2030)

8.1.12. Human Cells and Tissues

8.1.12.1. Market Revenue and Forecast (2017-2030)

8.1.13. Others

8.1.13.1. Market Revenue and Forecast (2017-2030)

Chapter 9. Global Biologics Market, By Disease

9.1. Biologics Market, by Disease, 2022-2030

9.1.1. Oncology

9.1.1.1. Market Revenue and Forecast (2017-2030)

9.1.2. Immunological Disorders

9.1.2.1. Market Revenue and Forecast (2017-2030)

9.1.3. Cardiovascular Disorders

9.1.3.1. Market Revenue and Forecast (2017-2030)

9.1.4. Hematological Disorders

9.1.4.1. Market Revenue and Forecast (2017-2030)

9.1.5. Others

9.1.5.1. Market Revenue and Forecast (2017-2030)

Chapter 10. Global Biologics Market, By Manufacturing

10.1. Biologics Market, by Manufacturing, 2022-2030

10.1.1. Outsourced

10.1.1.1. Market Revenue and Forecast (2017-2030)

10.1.2. In-house

10.1.2.1. Market Revenue and Forecast (2017-2030)

Chapter 11. Global Biologics Market, By Route of Administration

11.1. Biologics Market, by Route of Administration, 2022-2030

11.1.1. Oral

11.1.1.1. Market Revenue and Forecast (2017-2030)

11.1.2. Others (IV and IP)

11.1.2.1. Market Revenue and Forecast (2017-2030)

Chapter 12. Global Biologics Market, By Drug Classification

12.1. Biologics Market, by Drug Classification, 2022-2030

12.1.1. Branded Drugs

12.1.1.1. Market Revenue and Forecast (2017-2030)

12.1.2. Generic Drugs

12.1.2.1. Market Revenue and Forecast (2017-2030)

Chapter 13. Global Biologics Market, By Mode of Purchase

13.1. Biologics Market, by Mode of Purchase, 2022-2030

13.1.1. Prescription Drugs

13.1.1.1. Market Revenue and Forecast (2017-2030)

13.1.2. Over-The-Counter (OTC) Drugs

13.1.2.1. Market Revenue and Forecast (2017-2030)

Chapter 14. Global Biologics Market, Regional Estimates and Trend Forecast

14.1. North America

14.1.1. Market Revenue and Forecast, by Source (2017-2030)

14.1.2. Market Revenue and Forecast, by Product (2017-2030)

14.1.3. Market Revenue and Forecast, by Disease (2017-2030)

14.1.4. Market Revenue and Forecast, by Manufacturing (2017-2030)

14.1.5. Market Revenue and Forecast, by Route of Administration (2017-2030)

14.1.6. Market Revenue and Forecast, by Mode of Purchase (2017-2030)

14.1.7. Market Revenue and Forecast, by Drug Classification (2017-2030)

14.1.8. U.S.

14.1.8.1. Market Revenue and Forecast, by Source (2017-2030)

14.1.8.2. Market Revenue and Forecast, by Product (2017-2030)

14.1.8.3. Market Revenue and Forecast, by Disease (2017-2030)

14.1.8.4. Market Revenue and Forecast, by Manufacturing (2017-2030)

14.1.8.5. Market Revenue and Forecast, by Route of Administration (2017-2030)

14.1.8.6. Market Revenue and Forecast, by Mode of Purchase (2017-2030)

14.1.8.7. Market Revenue and Forecast, by Drug Classification (2017-2030)

14.1.9. Rest of North America

14.1.9.1. Market Revenue and Forecast, by Source (2017-2030)

14.1.9.2. Market Revenue and Forecast, by Product (2017-2030)

14.1.9.3. Market Revenue and Forecast, by Disease (2017-2030)

14.1.9.4. Market Revenue and Forecast, by Manufacturing (2017-2030)

14.1.9.5. Market Revenue and Forecast, by Route of Administration (2017-2030)

14.1.9.6. Market Revenue and Forecast, by Mode of Purchase (2017-2030)

14.1.9.7. Market Revenue and Forecast, by Drug Classification (2017-2030)

14.2. Europe

14.2.1. Market Revenue and Forecast, by Source (2017-2030)

14.2.2. Market Revenue and Forecast, by Product (2017-2030)

14.2.3. Market Revenue and Forecast, by Disease (2017-2030)

14.2.4. Market Revenue and Forecast, by Manufacturing (2017-2030)

14.2.5. Market Revenue and Forecast, by Route of Administration (2017-2030)

14.2.6. Market Revenue and Forecast, by Mode of Purchase (2017-2030)

14.2.7. Market Revenue and Forecast, by Drug Classification (2017-2030)

14.2.8. UK

14.2.8.1. Market Revenue and Forecast, by Source (2017-2030)

14.2.8.2. Market Revenue and Forecast, by Product (2017-2030)

14.2.8.3. Market Revenue and Forecast, by Disease (2017-2030)

14.2.8.4. Market Revenue and Forecast, by Manufacturing (2017-2030)

14.2.8.5. Market Revenue and Forecast, by Route of Administration (2017-2030)

14.2.8.6. Market Revenue and Forecast, by Mode of Purchase (2017-2030)

14.2.8.7. Market Revenue and Forecast, by Drug Classification (2017-2030)

14.2.9. Germany

14.2.9.1. Market Revenue and Forecast, by Source (2017-2030)

14.2.9.2. Market Revenue and Forecast, by Product (2017-2030)

14.2.9.3. Market Revenue and Forecast, by Disease (2017-2030)

14.2.9.4. Market Revenue and Forecast, by Manufacturing (2017-2030)

14.2.9.5. Market Revenue and Forecast, by Route of Administration (2017-2030)

14.2.9.6. Market Revenue and Forecast, by Mode of Purchase (2017-2030)

14.2.9.7. Market Revenue and Forecast, by Drug Classification (2017-2030)

14.2.10. France

14.2.10.1. Market Revenue and Forecast, by Source (2017-2030)

14.2.10.2. Market Revenue and Forecast, by Product (2017-2030)

14.2.10.3. Market Revenue and Forecast, by Disease (2017-2030)

14.2.10.4. Market Revenue and Forecast, by Manufacturing (2017-2030)

14.2.10.5. Market Revenue and Forecast, by Route of Administration (2017-2030)

14.2.10.6. Market Revenue and Forecast, by Mode of Purchase (2017-2030)

14.2.10.7. Market Revenue and Forecast, by Drug Classification (2017-2030)

14.2.11. Rest of Europe

14.2.11.1. Market Revenue and Forecast, by Source (2017-2030)

14.2.11.2. Market Revenue and Forecast, by Product (2017-2030)

14.2.11.3. Market Revenue and Forecast, by Disease (2017-2030)

14.2.11.4. Market Revenue and Forecast, by Manufacturing (2017-2030)

14.2.11.5. Market Revenue and Forecast, by Route of Administration (2017-2030)

14.2.11.6. Market Revenue and Forecast, by Mode of Purchase (2017-2030)

14.2.11.7. Market Revenue and Forecast, by Drug Classification (2017-2030)

14.3. APAC

14.3.1. Market Revenue and Forecast, by Source (2017-2030)

14.3.2. Market Revenue and Forecast, by Product (2017-2030)

14.3.3. Market Revenue and Forecast, by Disease (2017-2030)

14.3.4. Market Revenue and Forecast, by Manufacturing (2017-2030)

14.3.5. Market Revenue and Forecast, by Route of Administration (2017-2030)

14.3.6. Market Revenue and Forecast, by Mode of Purchase (2017-2030)

14.3.7. Market Revenue and Forecast, by Drug Classification (2017-2030)

14.3.8. India

14.3.8.1. Market Revenue and Forecast, by Source (2017-2030)

14.3.8.2. Market Revenue and Forecast, by Product (2017-2030)

14.3.8.3. Market Revenue and Forecast, by Disease (2017-2030)

14.3.8.4. Market Revenue and Forecast, by Manufacturing (2017-2030)

14.3.8.5. Market Revenue and Forecast, by Route of Administration (2017-2030)

14.3.8.6. Market Revenue and Forecast, by Mode of Purchase (2017-2030)

14.3.8.7. Market Revenue and Forecast, by Drug Classification (2017-2030)

14.3.9. China

14.3.9.1. Market Revenue and Forecast, by Source (2017-2030)

14.3.9.2. Market Revenue and Forecast, by Product (2017-2030)

14.3.9.3. Market Revenue and Forecast, by Disease (2017-2030)

14.3.9.4. Market Revenue and Forecast, by Manufacturing (2017-2030)

14.3.9.5. Market Revenue and Forecast, by Route of Administration (2017-2030)

14.3.9.6. Market Revenue and Forecast, by Mode of Purchase (2017-2030)

14.3.9.7. Market Revenue and Forecast, by Drug Classification (2017-2030)

14.3.10. Japan

14.3.10.1. Market Revenue and Forecast, by Source (2017-2030)

14.3.10.2. Market Revenue and Forecast, by Product (2017-2030)

14.3.10.3. Market Revenue and Forecast, by Disease (2017-2030)

14.3.10.4. Market Revenue and Forecast, by Manufacturing (2017-2030)

14.3.10.5. Market Revenue and Forecast, by Route of Administration (2017-2030)

14.3.10.6. Market Revenue and Forecast, by Mode of Purchase (2017-2030)

14.3.10.7. Market Revenue and Forecast, by Drug Classification (2017-2030)

14.3.11. Rest of APAC

14.3.11.1. Market Revenue and Forecast, by Source (2017-2030)

14.3.11.2. Market Revenue and Forecast, by Product (2017-2030)

14.3.11.3. Market Revenue and Forecast, by Disease (2017-2030)

14.3.11.4. Market Revenue and Forecast, by Manufacturing (2017-2030)

14.3.11.5. Market Revenue and Forecast, by Route of Administration (2017-2030)

14.3.11.6. Market Revenue and Forecast, by Mode of Purchase (2017-2030)

14.3.11.7. Market Revenue and Forecast, by Drug Classification (2017-2030)

14.4. MEA

14.4.1. Market Revenue and Forecast, by Source (2017-2030)

14.4.2. Market Revenue and Forecast, by Product (2017-2030)

14.4.3. Market Revenue and Forecast, by Disease (2017-2030)

14.4.4. Market Revenue and Forecast, by Manufacturing (2017-2030)

14.4.5. Market Revenue and Forecast, by Route of Administration (2017-2030)

14.4.6. Market Revenue and Forecast, by Mode of Purchase (2017-2030)

14.4.7. Market Revenue and Forecast, by Drug Classification (2017-2030)

14.4.8. GCC

14.4.8.1. Market Revenue and Forecast, by Source (2017-2030)

14.4.8.2. Market Revenue and Forecast, by Product (2017-2030)

14.4.8.3. Market Revenue and Forecast, by Disease (2017-2030)

14.4.8.4. Market Revenue and Forecast, by Manufacturing (2017-2030)

14.4.8.5. Market Revenue and Forecast, by Route of Administration (2017-2030)

14.4.8.6. Market Revenue and Forecast, by Mode of Purchase (2017-2030)

14.4.8.7. Market Revenue and Forecast, by Drug Classification (2017-2030)

14.4.9. North Africa

14.4.9.1. Market Revenue and Forecast, by Source (2017-2030)

14.4.9.2. Market Revenue and Forecast, by Product (2017-2030)

14.4.9.3. Market Revenue and Forecast, by Disease (2017-2030)

14.4.9.4. Market Revenue and Forecast, by Manufacturing (2017-2030)

14.4.9.5. Market Revenue and Forecast, by Route of Administration (2017-2030)

14.4.9.6. Market Revenue and Forecast, by Mode of Purchase (2017-2030)

14.4.9.7. Market Revenue and Forecast, by Drug Classification (2017-2030)

14.4.10. South Africa

14.4.10.1. Market Revenue and Forecast, by Source (2017-2030)

14.4.10.2. Market Revenue and Forecast, by Product (2017-2030)

14.4.10.3. Market Revenue and Forecast, by Disease (2017-2030)

14.4.10.4. Market Revenue and Forecast, by Manufacturing (2017-2030)

14.4.10.5. Market Revenue and Forecast, by Route of Administration (2017-2030)

14.4.10.6. Market Revenue and Forecast, by Mode of Purchase (2017-2030)

14.4.10.7. Market Revenue and Forecast, by Drug Classification (2017-2030)

14.4.11. Rest of MEA

14.4.11.1. Market Revenue and Forecast, by Source (2017-2030)

14.4.11.2. Market Revenue and Forecast, by Product (2017-2030)

14.4.11.3. Market Revenue and Forecast, by Disease (2017-2030)

14.4.11.4. Market Revenue and Forecast, by Manufacturing (2017-2030)

14.4.11.5. Market Revenue and Forecast, by Route of Administration (2017-2030)

14.4.11.6. Market Revenue and Forecast, by Mode of Purchase (2017-2030)

14.4.11.7. Market Revenue and Forecast, by Drug Classification (2017-2030)

14.5. Latin America

14.5.1. Market Revenue and Forecast, by Source (2017-2030)

14.5.2. Market Revenue and Forecast, by Product (2017-2030)

14.5.3. Market Revenue and Forecast, by Disease (2017-2030)

14.5.4. Market Revenue and Forecast, by Manufacturing (2017-2030)

14.5.5. Market Revenue and Forecast, by Route of Administration (2017-2030)

14.5.6. Market Revenue and Forecast, by Mode of Purchase (2017-2030)

14.5.7. Market Revenue and Forecast, by Drug Classification (2017-2030)

14.5.8. Brazil

14.5.8.1. Market Revenue and Forecast, by Source (2017-2030)

14.5.8.2. Market Revenue and Forecast, by Product (2017-2030)

14.5.8.3. Market Revenue and Forecast, by Disease (2017-2030)

14.5.8.4. Market Revenue and Forecast, by Manufacturing (2017-2030)

14.5.8.5. Market Revenue and Forecast, by Route of Administration (2017-2030)

14.5.8.6. Market Revenue and Forecast, by Mode of Purchase (2017-2030)

14.5.8.7. Market Revenue and Forecast, by Drug Classification (2017-2030)

14.5.9. Rest of LATAM

14.5.9.1. Market Revenue and Forecast, by Source (2017-2030)

14.5.9.2. Market Revenue and Forecast, by Product (2017-2030)

14.5.9.3. Market Revenue and Forecast, by Disease (2017-2030)

14.5.9.4. Market Revenue and Forecast, by Manufacturing (2017-2030)

14.5.9.5. Market Revenue and Forecast, by Route of Administration (2017-2030)

14.5.9.6. Market Revenue and Forecast, by Mode of Purchase (2017-2030)

14.5.9.7. Market Revenue and Forecast, by Drug Classification (2017-2030)

Chapter 15. Company Profiles

15.1. Eli Lilly & Company

15.1.1. Company Overview

15.1.2. Product Offerings

15.1.3. Financial Performance

15.1.4. Recent Initiatives

15.2. Samsung Biologics

15.2.1. Company Overview

15.2.2. Product Offerings

15.2.3. Financial Performance

15.2.4. Recent Initiatives

15.3. F Hoffman La Roche

15.3.1. Company Overview

15.3.2. Product Offerings

15.3.3. Financial Performance

15.3.4. Recent Initiatives

15.4. Celltrion Addgene

15.4.1. Company Overview

15.4.2. Product Offerings

15.4.3. Financial Performance

15.4.4. Recent Initiatives

15.5. Amgen

15.5.1. Company Overview

15.5.2. Product Offerings

15.5.3. Financial Performance

15.5.4. Recent Initiatives

15.6. Abbvie Inc.

15.6.1. Company Overview

15.6.2. Product Offerings

15.6.3. Financial Performance

15.6.4. Recent Initiatives

15.7. Sanofi

15.7.1. Company Overview

15.7.2. Product Offerings

15.7.3. Financial Performance

15.7.4. Recent Initiatives

15.8. Pfizer Inc.

15.8.1. Company Overview

15.8.2. Product Offerings

15.8.3. Financial Performance

15.8.4. Recent Initiatives

15.9. Merck & Co. Inc

15.9.1. Company Overview

15.9.2. Product Offerings

15.9.3. Financial Performance

15.9.4. Recent Initiatives

15.10. Novo Nordisk A/S

15.10.1. Company Overview

15.10.2. Product Offerings

15.10.3. Financial Performance

15.10.4. Recent Initiatives

Chapter 16. Research Methodology

16.1. Primary Research

16.2. Secondary Research

16.3. Assumptions

Chapter 17. Appendix

17.1. About Us

17.2. Glossary of Terms

Contact Us:

Precedence Research

Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada

Call: +1 774 402 6168

Email: sales@precedenceresearch.com

Website: https://www.precedenceresearch.com

 Blog: https://www.pharma-geek.com